Payment overview · 2025
General Payments
$2,658.65
76 reported records · 16 companies
Healthcare provider profile · identity verified
Janet I Sanchez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ELMHURST, NY · NPI 1962546499
Verified facts
What the public records show
CMS Open Payments records show Janet I Sanchez, M.D. received $2,658.65 in general payments during 2025 across 76 reported records.
AstraZeneca Pharmaceuticals LP accounted for 37.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Airsupra, Farxiga, Gemtesa, Kerendia, Ozempic, Paxlovid, Prolia, Qulipta, Rybelsus, Trelegy Ellipta, Xifaxan, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 473 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 229 claims for Ztlido by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $1,006.48 | 37.9% | 15 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $410.98 | 15.5% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $203.68 | 7.7% | 5 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $162.89 | 6.1% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $154.60 | 5.8% | 7 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $138.31 | 5.2% | 6 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $113.00 | 4.2% | 6 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $100.26 | 3.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $88.86 | 3.3% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $77.34 | 2.9% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $55.17 | 2.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43.94 | 1.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.33 | 1.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $25.00 | 0.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.40 | 0.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.41 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,643.65 | 75 |
| Education | $15.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $461.55 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $410.98 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $251.06 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $173.96 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $168.87 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $162.89 | 7 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $138.31 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $134.58 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $134.58 | 6 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $113.00 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $88.86 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $88.86 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $77.34 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $71.71 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $55.17 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $55.17 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $48.96 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $43.94 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.33 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $29.72 | 2 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $28.55 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $10.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 114 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 133 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 473 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 123 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 14 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 62 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 58 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 31 | exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 229 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
57 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
123 | 39 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
217 | 62 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
62 | 40 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
77 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
114 | 25 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
473 | 92 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
42 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
58 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
123 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
229 | 44 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
31 | 17 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
133 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Diclofenac Sodium | Diclofenac Sodium | 755 | 117 |
| Atorvastatin Calcium | Atorvastatin Calcium | 664 | 204 |
| Kerendia | Finerenone | 473 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 317 | 89 |
| Losartan Potassium | Losartan Potassium | 277 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 257 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 238 | 87 |
| Metformin Hcl | Metformin Hcl | 235 | 83 |
| Vascepa | Icosapent Ethyl | 231 | 76 |
| Ztlido | Lidocaine | 229 | 44 |
| Gabapentin | Gabapentin | 220 | 73 |
| Synthroid | Levothyroxine Sodium | 217 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 199 | 60 |
| Meloxicam | Meloxicam | 183 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 180 | 61 |
| Januvia | Sitagliptin Phosphate | 163 | 36 |
| Simvastatin | Simvastatin | 138 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 135 | 49 |
| Azelastine Hcl | Azelastine Hcl | 134 | 33 |
| Gemtesa | Vibegron | 133 | 32 |
| Famotidine | Famotidine | 129 | 53 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 53 |
| Memantine Hcl | Memantine Hcl | 126 | 46 |
| Mometasone Furoate | Mometasone Furoate | 125 | 50 |
| Linzess | Linaclotide | 123 | 39 |
| Ozempic | Semaglutide | 123 | 29 |
| Alendronate Sodium | Alendronate Sodium | 122 | 44 |
| Doxepin Hcl | Doxepin Hcl | 121 | 56 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 118 | 38 |
| Farxiga | Dapagliflozin Propanediol | 114 | 25 |
| Ibandronate Sodium | Ibandronate Sodium | 104 | 32 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 103 | 47 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 102 | 30 |
| Omeprazole | Omeprazole | 102 | 41 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 93 | 31 |
| Tradjenta | Linagliptin | 93 | 26 |
| Lisinopril | Lisinopril | 86 | 23 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 84 | 32 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 84 | 30 |
| Baclofen | Baclofen | 80 | 42 |
| Myrbetriq | Mirabegron | 77 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 28 |
| Dexlansoprazole Dr | Dexlansoprazole | 71 | 22 |
| Montelukast Sodium | Montelukast Sodium | 71 | 24 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 70 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 70 | 25 |
| Donepezil Hcl | Donepezil Hcl | 68 | 20 |
| Tresiba Flextouch U-200 | Insulin Degludec | 68 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 67 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 15 |
| Lidocaine | Lidocaine | 64 | 16 |
| Prolia | Denosumab | 62 | 40 |
| Meclizine Hcl | Meclizine Hcl | 61 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 60 | 16 |
| Procto-Med Hc | Hydrocortisone | 58 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | 18 |
| Creon | Lipase/Protease/Amylase | 57 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 16 |
| Mupirocin | Mupirocin | 57 | 21 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 56 | 18 |
| Megestrol Acetate | Megestrol Acetate | 56 | 18 |
| Carvedilol | Carvedilol | 55 | 19 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 52 | 11 |
| Xarelto | Rivaroxaban | 52 | 11 |
| Finasteride | Finasteride | 51 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 47 |
| Eliquis | Apixaban | 48 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 48 | 13 |
| Trulance | Plecanatide | 48 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 47 | 14 |
| Ketoconazole | Ketoconazole | 45 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 45 | 11 |
| Naproxen | Naproxen | 43 | 15 |
| Ammonium Lactate | Ammonium Lactate | 42 | 13 |
| Atenolol | Atenolol | 42 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 42 | 27 |
| Azithromycin | Azithromycin | 41 | 36 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 41 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | suppressed |
| Nystatin | Nystatin | 39 | 17 |
| Celecoxib | Celecoxib | 38 | 19 |
| Trazodone Hcl | Trazodone Hcl | 38 | 15 |
| Sertraline Hcl | Sertraline Hcl | 37 | 11 |
| Furosemide | Furosemide | 36 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 35 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 34 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 32 | suppressed |
| Ibuprofen | Ibuprofen | 32 | 12 |
| Lovastatin | Lovastatin | 32 | suppressed |
| Prednisone | Prednisone | 32 | 26 |
| Jardiance | Empagliflozin | 31 | suppressed |
| Levofloxacin | Levofloxacin | 31 | 29 |
| Xifaxan | Rifaximin | 31 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | 13 |
| Cefuroxime | Cefuroxime Axetil | 30 | 28 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 29 | 12 |
| Glimepiride | Glimepiride | 28 | suppressed |
| Livalo | Pitavastatin Calcium | 28 | suppressed |
| Repaglinide | Repaglinide | 28 | 13 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 27 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 27 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 26 | 11 |
| Estradiol | Estradiol | 26 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Fluocinonide | Fluocinonide | 25 | 15 |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 24 | suppressed |
| Budesonide Er | Budesonide | 24 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 21 | suppressed |
| Qulipta | Atogepant | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Allopurinol | Allopurinol | 20 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 20 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | 12 |
| Irbesartan | Irbesartan | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Calcipotriene | Calcipotriene | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Rivastigmine | Rivastigmine | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Vraylar | Cariprazine Hcl | 18 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 15 |
| Proctozone-Hc | Hydrocortisone | 17 | suppressed |
| Terconazole | Terconazole | 17 | 12 |
| Ryaltris | Olopatadine Hcl/Mometasone | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 15 | suppressed |
| Desoximetasone | Desoximetasone | 14 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Restasis | Cyclosporine | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Folic Acid | Folic Acid | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Budesonide Ec | Budesonide | 12 | suppressed |
| Bystolic | Nebivolol Hcl | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,658.65 · 76 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPVAXIVE, Cologuard Collection Kit, EVENITY, FARXIGA, GARDASIL 9, GEMTESA, IBSRELA, Kerendia, MYFEMBREE, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PROLIA, QULIPTA, REPATHA, Rybelsus, SAPHNELO, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Veozah, XIFAXAN, ZAVZPRET, ZORYVE, ZTLido | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Airsupra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error